Featured Press Releases

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

  • 17 Mar 2025

Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced...

Akebia

Akebia's Vafseo® (vadadustat) Tablets FDA Approved for Anemia Treatment in Dialysis Patients

Tempo Therapeutics Appoints Eric I. Richman to Board of Directors

Tempo Therapeutics Appoints Eric I. Richman to Board of Directors

Leqembi Secures Approval for Alzheimer

Leqembi Secures Approval for Alzheimer's Disease Treatment in Hong Kong

Precision BioSciences announces a U.S. patent covering PBGENE-HBV for chronic hepatitis B and provides updates on the program

Precision BioSciences announces a U.S. patent covering PBGENE-HBV for chronic hepatitis B and provides updates on the program's status

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

  • Aspera Biomedicines Inc.
  • 18 May 2026
Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

  • Galvanize Therapeutics, Inc.
  • 18 May 2026
Peter Menziuso named EVP and President of BD Interventional

Peter Menziuso named EVP and President of BD Interventional

  • BD
  • 18 May 2026
A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

  • Ferring Pharmaceuticals
  • 17 May 2026
Biohack skin longevity with Futurecode Booster

Biohack skin longevity with Futurecode Booster

  • Dermalogica
  • 16 May 2026
ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

  • AstraZeneca
  • 15 May 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.